Our study clarifies a microglial miR‐126a‐5p/MMP9 mediated novel mechanism underlying BBB integrity during inflammatory demyelination and suggests microglial targeting for BBB therapeutic intervention in MS progression. This evidence concerns the gene MMP9 and myeloid sarcoma.